Journey Medical CORP Form 4 insider transactions

Journey Medical Corp director Jayne Toledano Miranda was granted 10,000 restricted stock units on June 25, 2026, vesting on June 25, 2027.

Journey Medical Corp. director Justin Adam Smith was granted 10,000 restricted stock units on June 25, 2026, vesting on June 25, 2027.

Michael Cooper Pearce, a Director at Journey Medical Corp, was granted 10,000 restricted stock units on June 25, 2026, vesting on June 25, 2027.

Journey Medical Corp reports a grant of 10,000 restricted stock units to Director Lindsay A. Rosenwald, with vesting scheduled for June 25, 2027.

Journey Medical Corporation Chief Operating Officer Ramsey Alloush was granted 46,863 restricted stock units and 62,795 stock options.

CFO Joseph Benesch was granted 28,907 restricted stock units and 41,860 stock options as part of the company's 2015 Stock Plan.

CEO Claude Maraoui was granted 49,277 restricted stock units and 82,915 stock options as part of the company's 2015 Stock Plan.

Journey Medical Corp's President and CEO, Claude Maraoui, exercised 1.25 million stock options and adjusted common stock holdings, correcting a prior reporting error.

Journey Medical Corp's Director, Lindsay A. Rosenwald, MD, was granted 50,000 restricted stock units vesting over three years.

Journey Medical Corp Director Justin Adam Smith was granted 20,000 restricted stock units, vesting over three years.

Journey Medical Corp's Director, Miranda Jayne Toledano, was granted 20,000 restricted stock units vesting over three years.

Journey Medical Corp Director Michael Cooper Pearce was granted 20,000 restricted stock units, vesting over three years.

Journey Medical Corp Director Neil Herskowitz was granted 20,000 restricted stock units, vesting over three years starting in 2028.

Journey Medical Corp Director Miranda Jayne Toledano was granted 7,173 restricted stock units, vesting in June 2026, increasing her beneficial ownership to 88,618 shares.

Journey Medical Corp Director and 10% owner, Lindsay A. Rosenwald MD, reported the acquisition of 7,173 restricted stock units, which will vest in full on June 25, 2026.

Journey Medical Corp. Director Michael Cooper Pearce was granted 7,173 restricted stock units, increasing his beneficial ownership to 37,173 shares.

Journey Medical Corp Director Justin Adam Smith was granted 7,173 restricted stock units, vesting in full on June 25, 2026, as part of the company's 2015 Stock Plan.

Journey Medical Corp Director Neil Herskowitz was granted 7,173 restricted stock units on June 25, 2025, increasing his beneficial ownership to 88,618 shares.

Journey Medical Corp's Chief Operating Officer, Ramsey Alloush, was granted 46,863 restricted stock units and 62,795 stock options on June 17, 2025, as part of the company's 2015 Stock Plan.

Journey Medical Corp's Chief Financial Officer, Joseph Benesch, was granted 28,907 restricted stock units and 41,860 stock options under the company's 2015 Stock Plan.

Journey Medical Corp's President and CEO, Claude Maraoui, was granted 49,277 restricted stock units and 82,915 stock options, aligning executive compensation with future company performance.

Claude Maraoui, President & CEO of Journey Medical Corp, sold 4,834 shares to cover tax obligations related to vesting restricted stock units.

Journey Medical Corp's CFO, Joseph Benesch, sold 2,409 shares of common stock on May 2, 2025, to cover tax obligations related to vesting restricted stock units.

Ramsey Alloush, COO of Journey Medical Corp, sold 2,857 shares of common stock on May 2, 2025, to cover tax obligations related to vesting restricted stock units.

Claude Maraoui, President & CEO of Journey Medical Corp, reports the acquisition of 350,000 restricted stock units in two separate grants.

Joseph Benesch, CFO of Journey Medical Corp, reports the grant of 160,000 restricted stock units in two separate transactions, with vesting schedules extending to 2027, and discloses a late reporting of these transactions due to administrative error.

Claude Maraoui, President & CEO of Journey Medical Corp, sold 49,271 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

CEO Claude Maraoui sold shares of Journey Medical Corp stock to cover tax obligations related to vesting restricted stock units.

Claude Maraoui, President & CEO of Journey Medical Corp, sold shares of common stock between March 3rd and March 5th, 2025, to cover tax obligations related to vesting restricted stock units.

Journey Medical Corp's CFO, Joseph Benesch, sold 1,365 shares to cover tax obligations related to vesting restricted stock units.